Alnylam Pharmaceuticals, Inc.

ALNY

US02043Q1076

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-19 pm EDT			5-day change	1st Jan Change
144.4 ^USD	-0.52%		-2.75%	-24.55%

Apr. 08	Sector Update: Health Care Stocks Flat to Higher Premarket Monday	MT
Apr. 08	Sector Update: Health Care	MT

ALNYLAM PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (form 8-K)

February 27, 2020 at 04:42 pm EST

uto;border-bottom:1px solid #000000;width:21.05%;margin-right:auto;margin-top:9pt;margin-bottom:0px">

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 27, 2020 (February 26, 2020)

Alnylam Pharmaceuticals, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware

001-36407

77-0602661

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

Latest news about Alnylam Pharmaceuticals, Inc.

Sector Update: Health Care Stocks Flat to Higher Premarket Monday	Apr. 08	MT
Sector Update: Health Care	Apr. 08	MT
Alnylam Pharmaceuticals Says Phase 2 Trial for Zilebesiran Meets Primary Endpoint	Apr. 08	MT
ANALYST RECOMMENDATIONS : Chevron, Take-Two, Coinbase, Netflix, American Tower...	Apr. 08
Transcript : Alnylam Pharmaceuticals, Inc. - Special Call	Apr. 07
Alnylam Presents Positive Results from the KARDIA-2 Phase 2 Study of Zilebesiran Added to Standard of Care Antihypertensives in Patients with Inadequately Controlled Hypertension	Apr. 07	CI
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Canaccord Genuity ?Genetic Medicine for Generalists?, Mar-25-2024 01:00 PM	Mar. 25
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Stifel Virtual 2024 CNS Day, Mar-20-2024 10:00 AM	Mar. 20
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 10:15 AM	Mar. 12
Alnylam Pharmaceuticals Says Phase 2 Study of Hypertension Drug Zilebesiran Meets Primary Endpoint	Mar. 05	MT
Transcript : Alnylam Pharmaceuticals, Inc. Presents at TD Cowen 44th Annual Health Care Conference 2024, Mar-05-2024 09:10 AM	Mar. 05
Alnylam Reports Positive KARDIA-2 Topline Study Results Demonstrating Clinically Significant Blood Pressure Reductions When Zilebesiran Is Added to Standard of Care Antihypertensives	Mar. 05	CI
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,540,071, According to a Recent SEC Filing	Mar. 01	MT
Alnylam Pharmaceuticals Insider Sold Shares Worth $455,357, According to a Recent SEC Filing	Feb. 29	MT
How long will this bullish phase last?	Feb. 26
ANALYST RECOMMENDATIONS : AbbVie, Doordash, Eli Lilly, Moderna, Hiscox...	Feb. 26
ANALYST RECOMMENDATIONS : Airbnb, Conagra Brands, Berkshire Hathaway, Meta Platforms, Unilever....	Feb. 21
North American Morning Briefing : Earnings Back in -2-	Feb. 20	DJ
Chardan Cuts Price Target on Alnylam Pharmaceuticals to $225 From $250, Expects Topline Results in Mid-2024, Maintains Buy Rating	Feb. 16	MT
Goldman Sachs Downgrades Alnylam Pharmaceuticals to Neutral From Buy, Cuts Price Target to $173 From $230	Feb. 16	MT
ANALYST RECOMMENDATIONS : Coinbase, Fortinet, Nike, Chipotle, Nvidia...	Feb. 16
Alnylam Pharmaceuticals' Shares Fall on Q4 Revenue Miss	Feb. 15	MT
Wolfe Research Initiates Coverage on Alnylam Pharmaceuticals With Peer Perform Rating	Feb. 15	MT
Sector Update: Health Care Stocks Edge Higher Premarket Thursday	Feb. 15	MT
Transcript : Alnylam Pharmaceuticals, Inc., Q4 2023 Earnings Call, Feb 15, 2024	Feb. 15

Chart Alnylam Pharmaceuticals, Inc.

Duration

Period

More charts

Alnylam Pharmaceuticals, Inc. is a clinical-stage company. The Company is engaged in developing mRNA cell therapies for the treatment of autoimmune diseases. The Companyâs lead product candidate, Descartes-08, is an autologous mRNA CAR-T directed against the B cell maturation antigen (BCMA). Descartes-08 targets BCMA, which exists on the surface of long-lived plasma cells and plasmacytoid dendritic cells. Descartes-08 is in Phase IIb clinical development for patients with generalized myasthenia gravis (MG). Its other product candidate includes Descartes-15 and Descartes-33. Descartes-15 is a next-generation, autologous anti-BCMA mRNA CAR-T. Using its proprietary technology and manufacturing platform, it designed Descartes-15 to be more resistant than Descartes-08 to recycling of the CAR upon multiple antigen exposures. It is developing Descartes-33 to deliver a combination of therapeutic proteins that target key drivers in the pathogenesis of autoimmunity.

Sector

Biotechnology & Medical Research

Calendar

2024-05-02 - Q1 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Alnylam Pharmaceuticals, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

145.2 USD

Average target price

220 USD

Spread / Average Target

+51.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALNYLAM PHARMACEUTICALS, INC.	-24.55%	18.36B
IQVIA HOLDINGS INC.	-1.42%	41.35B
LONZA GROUP AG	+42.15%	40.38B
MODERNA, INC.	+1.97%	39.05B
CELLTRION, INC.	-14.19%	26.67B
ICON PUBLIC LIMITED COMPANY	+1.82%	24.07B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-4.07%	11.68B
MEDPACE HOLDINGS, INC.	+21.36%	11.6B
UNITED THERAPEUTICS CORPORATION	+8.20%	11.15B
BIO-TECHNE CORPORATION	-19.49%	9.78B

Other Biotechnology & Medical Research